Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:15 AM ET 8-K
Financial Results BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported financial results for the second quarter of 2026, highlighting the successful completion of its $168.3 million IPO in August. The company also noted clinical progress for BH-30643, which received FDA Fast Track designation for the treatment of advanced EGFR C797S-positive NSCLC.

Term
Q2 2026

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter. In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels.”

Jean Cui, Ph.D., Founder, President and Chief Executive Officer

“With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”

Jean Cui, Ph.D., Founder, President and Chief Executive Officer
7:14 AM ET 8-K
Shareholder Meeting Roivant Sciences Ltd. ROIV

Roivant Sciences Shareholder Meeting

Roivant Sciences Ltd. held its 2026 Annual General Meeting of Shareholders on September 16, 2026, where shareholders approved all three agenda proposals. Key outcomes included the re-election of Daniel Gold and Meghan FitzGerald as Class II directors, the ratification of Ernst & Young LLP as the independent auditor, and the advisory approval of executive compensation.

7:05 AM ET 8-K
Stock Buyback Cava Group, Inc. CAVA

Cava Group Announces $100M Stock Buyback

CAVA Group's Board of Directors has authorized a new share repurchase program to buy back up to $100 million of its common stock. The program is set to expire on September 17, 2027, and will be funded through existing cash and operational cash flows.

Value
$100M
Term
through Sep 2027
6:58 AM ET 8-K
Other 8-K Filing Sunshine Silver Mining & Refining Co SSMR

Sunshine Silver Mining & Refining Other 8-K Filing

Sunshine Silver Mining & Refining Company announced its inclusion in the VanEck Junior Gold Miners ETF (GDXJ), effective September 18, 2026. The inclusion occurs three months after the company's IPO and is expected to increase investor visibility and trading liquidity. Management remains focused on returning the Sunshine Mine to production by late 2028.

Counterparty
VanEck Junior Gold Miners ETF
6:53 AM ET 8-K
Leadership Change Pentair plc PNR

Pentair Leadership Change

Pentair plc appointed Louis V. Pinkham to its Board of Directors and the Audit and Finance Committee, effective September 17, 2026. Mr. Pinkham is classified as an independent director and will receive the company's standard non-employee director compensation.

Counterparty
Louis V. Pinkham
6:46 AM ET 8-K
Investor Presentation Nova Minerals Corp NVA

Nova Minerals Investor Presentation

Nova Minerals Corp filed a formal corporate presentation dated September 18, 2026, as an exhibit to its 8-K. The presentation provides a strategic update on the company's operations and was also made available on its corporate website.

6:45 AM ET 8-K
Leadership Change Adient plc ADNT

Adient Leadership Change

Adient plc announced that Peter H. Carlin will resign from the board of directors to join the company as Vice President, Finance on October 1, 2026, before being appointed Executive Vice President and CFO on November 16, 2026. He succeeds Mark A. Oswald, whose departure was previously announced. Carlin's compensation package includes an $820,000 base salary and a $4.25 million target equity award for fiscal 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.